0000912057-01-535225.txt : 20011019
0000912057-01-535225.hdr.sgml : 20011019
ACCESSION NUMBER: 0000912057-01-535225
CONFORMED SUBMISSION TYPE: POS AM
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20011012
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENZYME CORP
CENTRAL INDEX KEY: 0000732485
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061047163
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: POS AM
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-87449
FILM NUMBER: 1757660
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQ
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6172527500
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
POS AM
1
a2060910zposam.txt
POS AM
As filed with the Securities and Exchange Commission on October 12, 2001
Registration No. 333-87449
--------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
----------------------
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 06-1047163
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
ONE KENDALL SQUARE, CAMBRIDGE, MASSACHUSETTS 02139 (617) 252-7500
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
----------------------
PETER WIRTH
Executive Vice President and Chief Legal Officer
Genzyme Corporation
One Kendall Square
Cambridge, Massachusetts 02139
(617) 252-7500
(Name, address, including zip code, and telephone number, including area code,
of agent for service) with copies to:
PAUL KINSELLA
Palmer & Dodge LLP
One Beacon Street
Boston, Massachusetts 02108
(617) 573-0100
----------------------
Genzyme Corporation previously issued 617,200 shares (the "Shares")
of Genzyme Molecular Oncology Division common stock, $0.01 par value per
share ("Molecular Oncology Stock"), to Canadian Medical Discoveries Fund Inc.
("CMDF") when Genzyme Corporation acquired one-half of CMDF's interest in
StressGen/Genzyme LLC. Genzyme Corporation's Registration Statement on Form
S-3 (File No. 333-87449) registered the Shares for resale by CMDF. As of the
date of this Post-Effective Amendment, 319,100 of the Shares have been sold
pursuant to the Registration Statement. The remaining 298,100 of the Shares
are now eligible for sale pursuant to Rule 144(k) under the Securities Act of
1933, as amended. This Post-Effective Amendment is filed to deregister
298,100 shares of Molecular Oncology Stock that were not sold pursuant to the
Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this
Post-Effective Amendment No. 1 to the Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Cambridge,
Commonwealth of Massachusetts, on October 12, 2001.
GENZYME CORPORATION
By: /s/ MICHAEL S. WYZGA
--------------------------------------
Michael S. Wyzga
Senior Vice President, Finance
and Chief Financial Officer
2